{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:23:28Z","timestamp":1785417808467,"version":"3.56.0"},"reference-count":82,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies.\nPatients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1\u20132 FL between 1997 and 2016 in nine institutions were included.\nResults: The median PFS1, PFS2, and PFS3 were 8.1 years (95% confidence interval [CI]: 7\u20139.3 years), 4.2 years (95% CI: 2.8\u20135.6 years) and 2.2 years (95% CI 1.7\u20132.8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset. \nInterpretation: With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern.<\/jats:p>","DOI":"10.2340\/1651-226x.2024.24377","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:13:54Z","timestamp":1714986834000},"page":"267-272","source":"Crossref","is-referenced-by-count":1,"title":["Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice"],"prefix":"10.2340","volume":"63","author":[{"given":"Aino","family":"Rajamaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-591X","authenticated-orcid":false,"given":"Marc","family":"Sorigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roosa E.I.","family":"Prusila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milla E.L.","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Kuitunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mercadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taina","family":"Turpeenniemi-Hujanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Sunela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"59007","doi-asserted-by":"crossref","unstructured":"Lackraj T, Goswami R, Kridel R. Pathogenesis of follicular lymphoma. Best Pract Res Clin Haematol. 2018;31:2\u201314.","DOI":"10.1016\/j.beha.2017.10.006"},{"key":"59008","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.beha.2017.10.006","DOI":"10.1016\/j.beha.2017.10.006"},{"key":"59009","doi-asserted-by":"crossref","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, Lopez-Guillermo A, et al. Follicular lymphoma. Nat Rev Dis Prim. 2019;5:83.https:\/\/doi.org\/10.1038\/s41572-019-0132-x","DOI":"10.1038\/s41572-019-0132-x"},{"key":"59010","doi-asserted-by":"crossref","unstructured":"Magnano L, Alonso\u2010Alvarez S, Alcoceba M, Rivas\u2010Delgado A, Munta\u00f1ola A, Nadeu F, et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019;185:480\u2013491.","DOI":"10.1111\/bjh.15805"},{"key":"59011","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjh.15805","DOI":"10.1111\/bjh.15805"},{"key":"59012","doi-asserted-by":"crossref","unstructured":"Rajam\u00e4ki A, Hujo M, Sund R, Prusila REI, Kuusisto MEL, Kuitunen H, et al. Mortality among patients with low\u2010grade follicular lymphoma: a binational retrospective analysis. Cancer. 2022;128:2474\u20132482.","DOI":"10.1002\/cncr.34221"},{"key":"59013","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.34221","DOI":"10.1002\/cncr.34221"},{"key":"59014","doi-asserted-by":"crossref","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagno-sis, treatment and follow-up.Ann Oncol. 2016;27:v83\u2013v90.","DOI":"10.1093\/annonc\/mdw400"},{"key":"59015","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdw400","DOI":"10.1093\/annonc\/mdw400"},{"key":"59016","doi-asserted-by":"crossref","unstructured":"Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v181\u2013v183.","DOI":"10.1093\/annonc\/mdq184"},{"key":"59017","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdq184","DOI":"10.1093\/annonc\/mdq184"},{"key":"59018","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Dreyling M. Newly diagnosed follicular lymphoma: ESMO Clinical Recom-mendations for diagnosis, treatment and follow-up. Ann Oncol. 2007;18:ii63\u2013ii64.","DOI":"10.1093\/annonc\/mdm041"},{"key":"59019","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdm041","DOI":"10.1093\/annonc\/mdm041"},{"key":"59020","doi-asserted-by":"crossref","unstructured":"Sorigue M, Prusila REI, Jauhiainen J, Mercadal S, Postila A, Salmi P, et al. Incidence of solid cancer in patients with follicular lymphoma. Acta Oncol (Madr). 2019;58:1564\u20131569.","DOI":"10.1080\/0284186X.2019.1643918"},{"key":"59021","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2019.1643918","DOI":"10.1080\/0284186X.2019.1643918"},{"key":"59022","doi-asserted-by":"crossref","unstructured":"Zha J, Chen Q, Ye J, Yu H, Yi S, Zheng Z, et al. Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1\u20132 follicular lymphoma: a real-world multicenter study. Biomark Res. 2023;11:16.","DOI":"10.1186\/s40364-023-00462-z"},{"key":"59023","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s40364-023-00462-z","DOI":"10.1186\/s40364-023-00462-z"},{"key":"59024","doi-asserted-by":"crossref","unstructured":"Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, et al. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood. 2021;137:1124\u20131129.","DOI":"10.1182\/blood.2020007994"},{"key":"59025","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood.2020007994","DOI":"10.1182\/blood.2020007994"},{"key":"59026","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u2013349.","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"59027","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"59028","doi-asserted-by":"crossref","unstructured":"Rivas-Delgado A, Magnano L, Moreno-Vel\u00e1zquez M, Garc\u00eda O, Nadeu F, Mozas P, et al. Re-sponse duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2018;184:753\u2013759.","DOI":"10.1111\/bjh.15708"},{"key":"59029","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjh.15708","DOI":"10.1111\/bjh.15708"},{"key":"59030","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the mo-dern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:74.","DOI":"10.1038\/s41408-020-00340-z"},{"key":"59031","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41408-020-00340-z","DOI":"10.1038\/s41408-020-00340-z"},{"key":"59032","doi-asserted-by":"crossref","unstructured":"Link BK, Day B, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, et al. Second\u2010line and sub-sequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184:660\u2013663.","DOI":"10.1111\/bjh.15149"},{"key":"59033","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjh.15149","DOI":"10.1111\/bjh.15149"},{"key":"59034","doi-asserted-by":"crossref","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140\u2013147.","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"59035","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.1995.13.1.140","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"59036","doi-asserted-by":"crossref","unstructured":"Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond.EMBO J. 2021;40:e108389.","DOI":"10.15252\/embj.2021108389"},{"key":"59037","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.15252\/embj.2021108389","DOI":"10.15252\/embj.2021108389"},{"key":"59038","doi-asserted-by":"crossref","unstructured":"Sorigue M, Sancho JM. Current prognostic and predictive factors in follicular lymphoma. Ann Hematol. 2018;97:209\u2013227.","DOI":"10.1007\/s00277-017-3154-z"},{"key":"59039","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00277-017-3154-z","DOI":"10.1007\/s00277-017-3154-z"},{"key":"59040","doi-asserted-by":"crossref","unstructured":"Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, et al. Sex differences in lymphoma incidence and mortality by subtype: a population\u2010based study. Am J Hematol. 2023;98:23\u201330.","DOI":"10.1002\/ajh.26744"},{"key":"59041","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.26744","DOI":"10.1002\/ajh.26744"},{"key":"59042","doi-asserted-by":"crossref","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicu-lar lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma pro-gnostic factor project. J Clin Oncol. 2009;27:4555\u20134562.","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"59043","doi-asserted-by":"crossref","unstructured":"Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, et al. A Compa-rative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab. Clin Cancer Res. 2013;19:6624\u20136632.","DOI":"10.1158\/1078-0432.CCR-13-1120"},{"key":"59044","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1120","DOI":"10.1158\/1078-0432.CCR-13-1120"},{"key":"59045","unstructured":"Federico M, Vitolo U, Zinzani PL, Chisesi T, Cl\u00f2 V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000;95:783\u2013789."},{"key":"59046","doi-asserted-by":"crossref","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u20131265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"59047","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2003-12-4434","DOI":"10.1182\/blood-2003-12-4434"},{"key":"59048","doi-asserted-by":"crossref","unstructured":"Rajam\u00e4ki A, Sunela K, Prusila REI, Kuusisto MEL, Mercadal S, Selander T, et al. Female pa-tients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months. Leuk Lymphoma. 2021;62:1639\u20131647.","DOI":"10.1080\/10428194.2021.1872073"},{"key":"59049","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/10428194.2021.1872073","DOI":"10.1080\/10428194.2021.1872073"},{"key":"59050","doi-asserted-by":"crossref","unstructured":"Y\u0131ld\u0131r\u0131m M, Kaya V, Demirpen\u00e7e \u00d6, Payda\u015f S. Systematic review\/Meta-analysis The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. Arch Med Sci. 2015;4:708\u2013714.","DOI":"10.5114\/aoms.2015.53289"},{"key":"59051","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5114\/aoms.2015.53289","DOI":"10.5114\/aoms.2015.53289"},{"key":"59052","doi-asserted-by":"crossref","unstructured":"Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, et al. Pro-gnostic role of gender in diffuse large B-cell lymphoma treated with ritux-imab containing regimens: a Fondazione Italiana Linfomi\/Grupo de Estudos em Mol\u00e9stias Onco-Hematol\u00f3gicas retrospective study. Leuk Lymphoma. 2013;54:53\u201357.","DOI":"10.3109\/10428194.2012.691482"},{"key":"59053","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/10428194.2012.691482","DOI":"10.3109\/10428194.2012.691482"},{"key":"59054","doi-asserted-by":"crossref","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331\u20131344.","DOI":"10.1056\/NEJMoa1614598"},{"key":"59055","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1614598","DOI":"10.1056\/NEJMoa1614598"},{"key":"59056","doi-asserted-by":"crossref","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for di-agnosis, treatment and follow-up. Ann Oncol. 2021;32:298\u2013308.","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"59057","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"59058","doi-asserted-by":"crossref","unstructured":"Lockmer S, \u00d8stenstad B, Hagberg H, Holte H, Johansson A-S, Wahlin BE, et al. Chemot-herapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two nordic lymphoma group trials with more than 10 years of follow-up. J Clin Oncol. 2018;36:3315\u20133323.","DOI":"10.1200\/JCO.18.00262"},{"key":"59059","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.18.00262","DOI":"10.1200\/JCO.18.00262"},{"key":"59060","doi-asserted-by":"crossref","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37:2815\u20132824.","DOI":"10.1200\/JCO.19.01073"},{"key":"59061","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.19.01073","DOI":"10.1200\/JCO.19.01073"},{"key":"59062","doi-asserted-by":"crossref","unstructured":"Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin\u2019s lymphoma: correlat-ion of complete response, time-to-event and overall survival end points. Ann Oncol. 2011;22:1392\u20131403.","DOI":"10.1093\/annonc\/mdq615"},{"key":"59063","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdq615","DOI":"10.1093\/annonc\/mdq615"},{"key":"59064","doi-asserted-by":"crossref","unstructured":"Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175:1389\u20131398.","DOI":"10.1001\/jamainternmed.2015.2829"},{"key":"59065","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamainternmed.2015.2829","DOI":"10.1001\/jamainternmed.2015.2829"},{"key":"59066","doi-asserted-by":"crossref","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analy-sis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u20132522.","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"59067","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2014.59.7534","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"59068","doi-asserted-by":"crossref","unstructured":"Weibull CE, W\u00e4sterlid T, Wahlin BE, Andersson P-O, Ekberg S, Lockmer S, et al. Survival by first-line treatment type and timing of progression among follicular lymphoma patients: a national population-based study in Sweden. He-maSphere. 2023;7:e838.","DOI":"10.1097\/HS9.0000000000000838"},{"key":"59069","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/HS9.0000000000000838","DOI":"10.1097\/HS9.0000000000000838"},{"key":"59070","doi-asserted-by":"crossref","unstructured":"Rajam\u00e4ki A, Hujo M, Sund R, Prusila REI, Kuusisto MEL, Kuitunen H, et al. Link between disease status at 24 months and mortality in follicular lymphoma. Br J Hae-matol. 2022;199:458\u2013462.","DOI":"10.1111\/bjh.18423"},{"key":"59071","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjh.18423","DOI":"10.1111\/bjh.18423"},{"key":"59072","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Positron-emission tomography\u2013based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer. 2020;126:78\u201390.","DOI":"10.1016\/j.ejca.2019.12.006"},{"key":"59073","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.006","DOI":"10.1016\/j.ejca.2019.12.006"},{"key":"59074","doi-asserted-by":"crossref","unstructured":"Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104:1202\u20131208.","DOI":"10.3324\/haematol.2018.209015"},{"key":"59075","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3324\/haematol.2018.209015","DOI":"10.3324\/haematol.2018.209015"},{"key":"59076","doi-asserted-by":"crossref","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e8res H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicu-lar lymphoma. Am J Hematol. 2016;91:1096\u20131101.","DOI":"10.1002\/ajh.24492"},{"key":"59077","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.24492","DOI":"10.1002\/ajh.24492"},{"key":"59078","doi-asserted-by":"crossref","unstructured":"Mozas P, Sorigu\u00e9 M, Rivas\u2010Delgado A, Rivero A, Correa JG, Castillo C, et al. The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. Eur J Haematol. 2021;106:428\u2013432.","DOI":"10.1111\/ejh.13556"},{"key":"59079","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ejh.13556","DOI":"10.1111\/ejh.13556"},{"key":"59080","doi-asserted-by":"crossref","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126:851\u2013857.","DOI":"10.1182\/blood-2015-01-621375"},{"key":"59081","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2015-01-621375","DOI":"10.1182\/blood-2015-01-621375"},{"key":"59082","doi-asserted-by":"crossref","unstructured":"Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426\u20132433.","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"59083","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2006.09.3260","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"59084","doi-asserted-by":"crossref","unstructured":"Gine E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological sub-type are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006;17:1539\u20131545.","DOI":"10.1093\/annonc\/mdl162"},{"key":"59085","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdl162","DOI":"10.1093\/annonc\/mdl162"},{"key":"59086","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202\u20131208.","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"59087","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2008.18.1495","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"59088","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Cancer Stat Facts: NHL \u2014 Follicular Lymphoma https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html March 2024"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/24377\/46021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/24377\/46021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:03:42Z","timestamp":1756404222000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/24377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":82,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2024.24377","relation":{},"ISSN":["1651-226X","0284-186X"],"issn-type":[{"value":"1651-226X","type":"electronic"},{"value":"0284-186X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}